Imunon Inc Quick Ratio (IMNN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Imunon Inc   (NASDAQ: IMNN)

Imunon Inc 's Quick Ratio

IMNN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Imunon Inc 's Cash & cash equivalent grew by 43.93 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Imunon Inc 's Quick Ratio to 1.44, Quick Ratio remained below Imunon Inc average.

Within Major Pharmaceutical Preparations industry 322 other companies have achieved higher Quick Ratio than Imunon Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1652 to 1788.

Explain Quick Ratio?
How much Cash & cash equivalents IMNN´s has?
What are IMNN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMNN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -3.17 % -30.63 % -2.68 % -22.9 % 8.2 %
Y / Y Cash & cash equivalent Change 45.92 % 66.94 % 49.52 % -49.08 % -10.89 %
Quick Ratio MRQ 1.44 1.28 2.08 1.38 0.96
IMNN's Total Ranking # 1788 # 1652 # 1928 # 2402 # 3072
Seq. Current Liabilities Change 27.53 % -11.15 % 10.88 % -22.92 % -8.64 %
Seq. Cash & cash equivalent Change 43.93 % -45.4 % 67.23 % 11.04 % 64.66 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 323
Healthcare Sector # 574
Overall Market # 1674


Quick Ratio Statistics
High Average Low
10.85 3.75 0.23
(Jun 30 2021)   (Dec 31 2011)




Financial Statements
Imunon Inc 's Current Liabilities $ 5 Millions Visit IMNN's Balance sheet
Imunon Inc 's Cash & cash equivalent $ 7 Millions Visit IMNN's Balance sheet
Source of IMNN's Sales Visit IMNN's Sales by Geography


Cumulative Imunon Inc 's Quick Ratio

IMNN's Quick Ratio for the trailling 12 Months

IMNN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -15.59 % -13.14 % 1.18 % -10.82 % -4.97 %
Y / Y Cash & cash equivalent TTM Growth 8.16 % -3.32 % -30.89 % -54.47 % -52.61 %
Quick Ratio TTM 1.55 1.41 1.18 1.01 1.21
Total Ranking TTM # 1080 # 1392 # 1173 # 1050 # 1036
Seq. Current Liabilities TTM Growth -0.94 % -9.01 % -0.63 % -5.76 % 1.94 %
Seq. Cash & cash equivalent TTM Growth 9.22 % 8.89 % 15.53 % -21.28 % -2.37 %

Quick ratio ranking by company, industry and sector >> Back to IMNN Financial Strength Comparisons >> Go to Compare IMNN Quick Ratio to its Competitors

On the trailing twelve months basis IMNN Cash & cash equivalent soared by 45.92 % in Q2 2026 year on year, while Current Liabilities grew to $5 millions, this led to increase in in Imunon Inc 's Quick Ratio to 1.55, Quick Ratio remained below IMNN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Imunon Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2014.

Explain Quick Ratio?
How much Cash & cash equivalents IMNN´s has?
What are IMNN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 886
Within the Market # 1788


trailing twelve months Quick Ratio Statistics
High Average Low
4.32 1.6 0.45
(Dec 31 2021)   (Jun 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Alx Oncology Holdings Inc  3.97 $ 22.753  Millions$ 5.731  Millions
Actinium Pharmaceuticals Inc  3.94 $ 36.473  Millions$ 9.260  Millions
Veru Inc   3.88 $ 23.880  Millions$ 6.156  Millions
Gain Therapeutics inc  3.81 $ 13.084  Millions$ 3.434  Millions
Bolt Biotherapeutics Inc   3.79 $ 29.823  Millions$ 7.867  Millions
Acurx Pharmaceuticals inc   3.72 $ 10.656  Millions$ 2.865  Millions
Maplight Therapeutics Inc   3.71 $ 71.633  Millions$ 19.294  Millions
Aptevo Therapeutics Inc   3.47 $ 17.997  Millions$ 5.188  Millions
Ataibeckley Inc   3.43 $ 168.807  Millions$ 49.221  Millions
Dogwood Therapeutics inc   3.40 $ 9.628  Millions$ 2.831  Millions
Tvardi Therapeutics Inc   3.39 $ 30.865  Millions$ 9.113  Millions
Biomea Fusion Inc   3.32 $ 34.824  Millions$ 10.483  Millions
Abeona Therapeutics Inc   3.32 $ 146.826  Millions$ 44.233  Millions
Foghorn Therapeutics Inc   3.31 $ 167.582  Millions$ 50.579  Millions
Cingulate Inc   3.29 $ 28.403  Millions$ 8.631  Millions
Unicycive Therapeutics Inc  3.28 $ 61.425  Millions$ 18.704  Millions
Harmony Biosciences Holdings inc   3.17 $ 667.791  Millions$ 210.812  Millions
Pulmatrix Inc   3.15 $ 2.168  Millions$ 0.689  Millions
Nextcure Inc   3.13 $ 20.088  Millions$ 6.413  Millions
Dianthus Therapeutics Inc   3.13 $ 107.611  Millions$ 34.389  Millions
Tg Therapeutics Inc   3.02 $ 811.665  Millions$ 268.493  Millions
Dermata Therapeutics Inc   3.02 $ 4.413  Millions$ 1.462  Millions
Xilio Therapeutics Inc   2.99 $ 136.040  Millions$ 45.487  Millions
Cadrenal Therapeutics Inc  2.99 $ 4.476  Millions$ 1.497  Millions
Zevra Therapeutics Inc   2.99 $ 145.321  Millions$ 48.632  Millions
Inhibitor Therapeutics Inc   2.95 $ 0.516  Millions$ 0.175  Millions
Annovis Bio Inc   2.95 $ 18.736  Millions$ 6.359  Millions
Puma Biotechnology Inc   2.89 $ 144.164  Millions$ 49.825  Millions
Ptc Therapeutics inc   2.89 $ 2,229.082  Millions$ 771.068  Millions
Werewolf Therapeutics Inc   2.80 $ 21.987  Millions$ 7.863  Millions

Date modified: 2026-09-12T06:13:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.